TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06680466
Drug: YZJ-4729
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Group 1
Study: NCT06680466
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06680466
Drug: YZJ-4729
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Group 2
Study: NCT06680466
Drug: YZJ-4729
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Group 3
Study: NCT05693675
Drug: Rescue Analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
Study: NCT05891587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution
Study: NCT04775082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
Study: NCT05615623
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin infusion
Study: NCT06680466
Drug: YZJ-4729
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Group 4
Study: NCT06206876
Drug: DDX5 Degrader FL118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06681038
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses.
Study: NCT04588428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
Study: NCT06251310
Drug: SW-682
Approvals — FDA: no, EMA: no, PMDA: no
Description: SW-682 tablet administered orally
Study: NCT06717880
Drug: IBI363 + Furuitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI363 Q2W or Q3W IV，Furuitinib po
Study: NCT06066125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
Study: NCT04974138
Drug: Amlodipine besylate and folic acid
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
Study: NCT04974138
Drug: Amlodipine-folic acid placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
Study: NCT05473273
Drug: Endometrin 100Mg Vaginal Insert
Normalized name: Endometrin 100mg Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
Study: NCT04684485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
Study: NCT04684485
Drug: SCD-044_Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
Study: NCT04684485
Drug: SCD-044_Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
Study: NCT04684485
Drug: SCD-044_Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
Study: NCT04850495
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04850495
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04677816
Drug: Standard of Care Neoadjuvant Chemotherapy (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.
Study: NCT06680609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
Study: NCT06680388
Drug: Drug：CD19 CAR-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
Study: NCT06690996
Drug: LY4005130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06690996
Drug: LY4005130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06690996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06690996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06393712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intrathecally
Study: NCT06393712
Drug: ALN-APP
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ALN-APP will be administered intrathecally
Study: NCT06058702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
Study: NCT06447506
Drug: GSK1070806
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive GSK1070806.
Study: NCT05253651
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
Study: NCT05253651
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
Study: NCT06277934
Drug: RGT001-075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06277934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05585814
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 3 cycles
Study: NCT06699342
Drug: Pharmacologic therapy optimized for Atrial Fibrillation management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.~Treatment is tailored based on patient tolerance and clinical efficacy.
Study: NCT05200403
Drug: Vehicle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
Study: NCT04675788
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will apply transdermal testosterone gel once daily every morning for 3 days
Study: NCT04675788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose capsules
Study: NCT06708481
Drug: P11-4, a self-assembling peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: rationally designed peptide, the monomers of which self-assemble into a biocompatible fibrillar scaffold that mimics the enamel matrix in response to particular environmental cues
Study: NCT06708481
Drug: P11-4, a self-assembling peptide with flouride
Approvals — FDA: no, EMA: no, PMDA: no
Description: self assembling peptide with 500 ppm sodium fluoride
Study: NCT06710704
Drug: Methylprednisolone and mepacaine
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
Study: NCT06707493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets are taken orally.
Study: NCT05856448
Drug: GLPG3667
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05856448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT06315335
Drug: UCB9741
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
Study: NCT06315335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
Study: NCT06632938
Drug: Placebo for ABBV-382
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06632938
Drug: Placebo for ABBV-382
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Injection
Study: NCT06322342
Drug: RVP-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI contrast agent
Study: NCT04669821
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
Study: NCT06706362
Drug: Bactrim or Macrobid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be assigned to Bactrim or Macrobid depending on participants' allergies
Study: NCT06706362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be assigned to identical appearing placebo
Study: NCT05737940
Drug: AZD3427
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
Study: NCT05737940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
Study: NCT05255991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered QID
Study: NCT05615415
Drug: PET Tracer
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
Study: NCT05615415
Drug: MRI Tracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected via intravenous catheter during PET-MR scanning.
Study: NCT06710665
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT06707480
Drug: Taurolidine and Heparin
Normalized name: heparin / taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter Lock Solution
Study: NCT05947474
Drug: ORB-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ORB-011 is dosed via IV infusion
Study: NCT05073458
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered QD orally follwed by Parsaclisinib in the open label period
Study: NCT05971485
Drug: Melatonin 10 mg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
Study: NCT04680221
Drug: Deposition of saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deposition of saline
Study: NCT05480878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT04464980
Drug: SL-BUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of sublingual buprenorphine-naloxone
Study: NCT04464980
Drug: XR-BUP
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly/monthly dosing of extended-release injectable buprenorphine
Study: NCT04464980
Drug: XR-NTX
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dosing of extended-release injectable naltrexone
Study: NCT04656535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo comparator for pre-surgery treatment in cohort B4
Study: NCT04704843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
Study: NCT05912517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an intravenous infusion.
Study: NCT06270680
Drug: Vision Edge Pro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose will consist of one supplement capsule containing 10 mg lutein, 2 mg zeaxanthin, 10 mg mesozeaxanthin, 50mg EPA, 250mg DHA. Capsules are to be taken orally, once daily with a meal. Duration of supplementation will last approximately 2 - 5 months, depending on the length of the athletic seasons for the sports recruited.
Study: NCT05873673
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: cystic jaw defect filled with placebo gel
Study: NCT06499857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3ml pen-injector containing placebo solution for subcutaneous use.
Study: NCT06315231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive one placebo twice daily for 24 weeks
Study: NCT04251182
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily in the morning
Study: NCT05605899
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05605899
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06261671
Drug: antioxidants-enriched culture medium (Gx)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blastocyst will be in continuous culture conditions (parallel antioxidants-enriched culture medium (Gx) and Global total one step media (GT) without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
Study: NCT04455750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06207877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT06125808
Drug: HRO350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active substance phospholipid esters from herring roe oil (PEHeRo)
Study: NCT06125808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
Study: NCT06175832
Drug: Elonva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection
Study: NCT06175832
Drug: Puregon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple injections
Study: NCT06175832
Drug: Orgalutran®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple injections
Study: NCT06175832
Drug: Gonapeptyl®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection
Study: NCT06175832
Drug: Cerazette®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05917509
Drug: DTG/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/3TC FDC will be administered as an oral once daily tablet.
Study: NCT06393101
Drug: BRC-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.
Study: NCT06393101
Drug: BRC-002 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of mono-, di-, and triglycerides
Study: NCT06205485
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2
Study: NCT06205485
Drug: Fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2
Study: NCT06205485
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m2 twice daily for 14 days
Study: NCT05712356
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following will be given every 14 days:~* oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion~* fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes~* fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)
Study: NCT05712356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
Study: NCT05546411
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
Study: NCT05546411
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study: NCT06014905
Drug: Hyperpolarized carbon C 13 pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Intravenously (IV)
Study: NCT04501614
Drug: Chemotherapy Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
Study: NCT05009069
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
Study: NCT05009069
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
Study: NCT06173934
Drug: insulin injection 15 minutes before meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjust insulin injection time to observe blood glucose spectrum
Study: NCT06173934
Drug: Insulin injection 15 minutes after eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjust insulin injection time to observe blood glucose spectrum
Study: NCT05482542
Drug: Cyclophosphamide/ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide/ATG
Study: NCT04951622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as an IV infusion.
Study: NCT03593317
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
Study: NCT03593317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.